Presage believes the most important model for understanding cancer drug response is the human body.
Presage uses CIVO®, a platform that enables assessment of multiple early stage agents simultaneously and directly in the context in which they were meant to be used—the human patient.
Clinical data, faster
With CIVO, Presage tests FDA-defined microdoses of anti-cancer agents directly in a patient's tumor, allowing for rapid de-risking of novel drugs with more efficiency than traditional Phase 1 trials.
The patented CIVO platform comprises a microinjector and drug loading device, coupled with fluorescent tracking microspheres. This device is intended to enable intratumoral microdosing of cancer agents.Learn More